AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16003061 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between forced expiratory volume in 1 sec and SGRQ domains
Number of subjects: 73
Study 12011878 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block for labor analgesia
Number of subjects: 4
Study 12011878 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block
Number of subjects: 4
Study 10732143 — intervention group
Group type: EXPERIMENTAL
Intervention: LH (Luteinizing Hormone)
Number of subjects: 6
Study 10732143 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH (Follicle Stimulating Hormone)
Number of subjects: 6
Study 10732143 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH and LH concentrations
Number of subjects: 6
Study 7496933 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1,000 mg every 6 h for 2 days)
Number of subjects: 80
Study 7496933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 7496933 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 80
Study 7496933 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy elderly subjects
Number of subjects: 80
Study 7496933 — intervention group
Group type: EXPERIMENTAL
Intervention: Infirm elderly subjects
Number of subjects: 80
Study 7496933 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional activity score
Number of subjects: 80
Study 2683263 — intervention group
Group type: EXPERIMENTAL
Intervention: Antilymphocyte globulin (ALG) and prednisone
Number of subjects: 45
Study 2683263 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA) 10 mg/kg/day and prednisone
Number of subjects: 45
Study 890617 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of prophylactic systemic antibiotics in high-risk patients
Number of subjects: 444
Study 890617 — intervention group
Group type: COMPARATOR
Intervention: No specific control intervention mentioned
Number of subjects: 444
Study 31943807 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused therapy (FFT)
Number of subjects: 94
Study 31943807 — intervention group
Group type: COMPARATOR
Intervention: Enhanced care (EC)
Number of subjects: 94
Study 31943807 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (NAPLS2)
Number of subjects: 94
Study 29962339 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide therapy
Number of subjects: 0
Study 26895652 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic light application (DLA) therapy, administered through ceiling-mounted fluorescent tubes delivering bluish-white light up to 1700 lux between 0900 h and 1600 h, except for 1130-1330 h when dimmed to 300 lux.
Number of subjects: 734
Study 26895652 — intervention group
Group type: COMPARATOR
Intervention: Normal lighting (control), with light levels at 300 lux and lights could be turned on and off from inside the room.
Number of subjects: 734
Study 24388379 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 0.025% ophthalmic solution, one drop twice daily for 28 days
Number of subjects: 75
Study 24388379 — intervention group
Group type: COMPARATOR
Intervention: Olopatadine 0.1% ophthalmic solution, one drop twice daily for 28 days
Number of subjects: 75
Study 24388379 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 0.025% ophthalmic solution
Number of subjects: 75
Study 22704725 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT vaccine
Number of subjects: 271
Study 19800329 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) with stainless steel electrode wires placed alongside the median nerve for immediate 1 h 20 Hz bipolar ES after CTRS
Number of subjects: 0
Study 19800329 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electrical stimulation)
Number of subjects: 0
Study 19800329 — intervention group
Group type: COMPARATOR
Intervention: Both stimulation and control groups
Number of subjects: 0
Study 18376350 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 40
Study 18376350 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose load
Number of subjects: 40
Study 18376350 — intervention group
Group type: EXPERIMENTAL
Intervention: Incretin effect calculated using insulin responses
Number of subjects: 40
Study 18376350 — intervention group
Group type: EXPERIMENTAL
Intervention: Incretin effect calculated using C-peptide responses
Number of subjects: 40
Study 15649722 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg acetylsalicylic acid (ASA)
Number of subjects: 100
Study 15649722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12165118 — intervention group
Group type: EXPERIMENTAL
Intervention: DITPA 1.875 mg/kg daily for 2 weeks, then 3.75 mg/kg daily for 2 weeks
Number of subjects: 19
Study 12165118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10442508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger rhizome extract (2 x 100 mg)
Number of subjects: 12
Study 7842149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening at 16 to 22 weeks' gestation and at 31 to 35 weeks' gestation
Number of subjects: 0
Study 7842149 — intervention group
Group type: COMPARATOR
Intervention: Control group received ultrasound screening only for medical indications
Number of subjects: 0
Study 2171375 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 56
Study 2171375 — intervention group
Group type: COMPARATOR
Intervention: Halothane anaesthesia
Number of subjects: 56
Study 2171375 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia and Halothane anaesthesia
Number of subjects: 56
Study 580623 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylthiouracil, 150 mg every eight hours
Number of subjects: 49
Study 580623 — intervention group
Group type: COMPARATOR
Intervention: Propylthiouracil, 450 mg as a single daily dose
Number of subjects: 49
Study 580623 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to propylthiouracil, 150 mg every eight hours after initial failure
Number of subjects: 49
Study 31506766 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic milk intake during the first half of pregnancy
Number of subjects: 57134
Study 30614469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib plus obinutuzumab
Number of subjects: 0
Study 30614469 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil plus obinutuzumab
Number of subjects: 0
Study 28913846 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (220 mL daily for 5 days)
Number of subjects: 100
Study 28913846 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional medical therapies only)
Number of subjects: 100
Study 25324220 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD-delivered exercise intervention
Number of subjects: 237
Study 25324220 — intervention group
Group type: COMPARATOR
Intervention: Attentional control condition
Number of subjects: 237
Study 23894426 — intervention group
Group type: EXPERIMENTAL
Intervention: Green exercise (rural environment)
Number of subjects: 75
Study 23894426 — intervention group
Group type: COMPARATOR
Intervention: Urban exercise (urban environment)
Number of subjects: 75
Study 23894426 — intervention group
Group type: COMPARATOR
Intervention: Control condition (urban exercise)
Number of subjects: 75
Study 21744383 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured autobiographical writing workshop
Number of subjects: 51
Study 21744383 — intervention group
Group type: COMPARATOR
Intervention: Reminiscence group (active control condition)
Number of subjects: 51
Study 21744383 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 51
Study 18623166 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass measurements (weight, height, body mass)
Number of subjects: 101
Study 18623166 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean tissue
Number of subjects: 101
Study 18623166 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat tissue
Number of subjects: 101
Study 18623166 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in body mass variables
Number of subjects: 101
Study 17115317 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber Band Ligation (RBL)
Number of subjects: 94
Study 17115317 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared Coagulation (IRC)
Number of subjects: 94
Study 17115317 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RBL and IRC
Number of subjects: 94
Study 15386864 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 18
Study 15386864 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Up Bond F
Number of subjects: 18
Study 15386864 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop
Number of subjects: 18
Study 11171519 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 detection thresholds
Number of subjects: 16
Study 11171519 — intervention group
Group type: EXPERIMENTAL
Intervention: VOC localization thresholds
Number of subjects: 16
Study 11171519 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal allergies
Number of subjects: 16
Study 11171519 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 and VOC measures
Number of subjects: 16
Study 9392401 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone, 50 mg/kg (single i.m. injection, with a second dose if unsatisfactory response after 48 h)
Number of subjects: 215
Study 9392401 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin clavulanate, 12.5 mg tid (10-day course)
Number of subjects: 215
Study 9392401 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin clavulanate
Number of subjects: 215
Study 9392401 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 215
Study 7930480 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (20 mg orally; n = 8)
Number of subjects: 14
Study 7930480 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 14
Study 3064333 — intervention group
Group type: EXPERIMENTAL
Intervention: Titan S air turbine scaler
Number of subjects: 12
Study 3064333 — intervention group
Group type: COMPARATOR
Intervention: Hand instruments
Number of subjects: 12
Study 28926120 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (G/P) for 12 weeks
Number of subjects: 131
Study 28926120 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (G/P) for 16 weeks
Number of subjects: 131
Study 27370229 — intervention group
Group type: EXPERIMENTAL
Intervention: eCoFit intervention (20-week multi-component intervention including outdoor training and cognitive mentoring in Phase 1 and smartphone application in Phase 2)
Number of subjects: 0
Study 27370229 — intervention group
Group type: EXPERIMENTAL
Intervention: eCoFit smartphone application (Phase 2)
Number of subjects: 0
Study 25534579 — intervention group
Group type: EXPERIMENTAL
Intervention: NEUROvitalis (NV) cognitive training
Number of subjects: 47
Study 25534579 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentally fit (MF) cognitive training
Number of subjects: 47
Study 25534579 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (CG)
Number of subjects: 47
Study 23473061 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic appendectomy
Number of subjects: 102
Study 23473061 — intervention group
Group type: COMPARATOR
Intervention: Three-port laparoscopic appendectomy
Number of subjects: 102
Study 20946120 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory nausea (AN)
Number of subjects: 214
Study 19114761 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine and Ketorolac administered 1 hr prior to skin incision
Number of subjects: 40
Study 19114761 — intervention group
Group type: COMPARATOR
Intervention: Morphine and Ketorolac administered at peritoneum closure
Number of subjects: 40
Study 16488321 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg subcutaneous weekly
Number of subjects: 157
Study 16488321 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 157
Study 16488321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 14615702 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 1348
Study 14615702 — intervention group
Group type: COMPARATOR
Intervention: SSRI
Number of subjects: 1348
Study 10915070 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygote children (wild type [wt]/Delta32)
Number of subjects: 457
Study 10915070 — intervention group
Group type: COMPARATOR
Intervention: Wild type (wt/wt) children
Number of subjects: 457
Study 8678775 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime sodium (1 g)
Number of subjects: 1070
Study 8678775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin plus clavulanic acid (3.1 g)
Number of subjects: 1070
Study 8678775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone sodium (1 g)
Number of subjects: 1070
Study 1811428 — intervention group
Group type: EXPERIMENTAL
Intervention: Square wave
Number of subjects: 120
Study 1811428 — intervention group
Group type: EXPERIMENTAL
Intervention: Postsynaptic wave
Number of subjects: 120
Study 1811428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 1811428 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 120
Study 6139529 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone (20 mg/kg)
Number of subjects: 60
Study 6139529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 6139529 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 60
Study 30357332 — intervention group
Group type: EXPERIMENTAL
Intervention: G1P[8] rotavirus vaccine (2-3 doses)
Number of subjects: 166
Study 30156433 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management for alcohol
Number of subjects: 114
Study 30156433 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management for other drug
Number of subjects: 114
Study 30156433 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management for both substances
Number of subjects: 114
Study 30156433 — intervention group
Group type: COMPARATOR
Intervention: No contingency management for either substance
Number of subjects: 114
Study 26839145 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 511
Study 26839145 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus cetuximab
Number of subjects: 511
Study 24715424 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose (30 g day(-1) for 6 weeks)
Number of subjects: 22
Study 24715424 — intervention group
Group type: COMPARATOR
Intervention: Cellulose (control)
Number of subjects: 22
Study 22244522 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube shunt (350‐mm² Baerveldt glaucoma implant)
Number of subjects: 105
Study 22244522 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C (MMC 0.4 mg/mL for 4 minutes)
Number of subjects: 105
Study 22244522 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube shunt
Number of subjects: 105
Study 22244522 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C
Number of subjects: 105
Study 20807969 — intervention group
Group type: EXPERIMENTAL
Intervention: Social intervention
Number of subjects: 123
Study 20807969 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (social intervention + antidepressants)
Number of subjects: 123
Study 20807969 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 123
Study 18399030 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1 mg/kg)
Number of subjects: 30
Study 18399030 — intervention group
Group type: COMPARATOR
Intervention: Etomidate (0.2 mg/kg)
Number of subjects: 30
Study 18399030 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 18399030 — intervention group
Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 30
Study 14693573 — intervention group
Group type: EXPERIMENTAL
Intervention: ADP receptor antagonist alone
Number of subjects: 93
Study 14693573 — intervention group
Group type: EXPERIMENTAL
Intervention: ADP receptor antagonist plus IV heparin
Number of subjects: 93
Study 14693573 — intervention group
Group type: COMPARATOR
Intervention: No preoperative treatment
Number of subjects: 93
Study 11964722 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary antioxidants; specific dosage and duration not available
Number of subjects: 0
Study 9721148 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide enema 2.0 mg/100 mL
Number of subjects: 233
Study 9721148 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide enema 8.0 mg/100 mL
Number of subjects: 233
Study 9721148 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide enema (both doses)
Number of subjects: 233
Study 9721148 — intervention group
Group type: COMPARATOR
Intervention: Placebo enema
Number of subjects: 233
Study 8052432 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 39
Study 8052432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 3056816 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic human proinsulin (assumed potency 4 U/mg)
Number of subjects: 7
Study 3056816 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 7
Study 8436094 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU vitamin A and 40 IU vitamin E)
Number of subjects: 172
Study 8436094 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 172
Study 8436094 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 172
Study 8436094 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 172
Study 219500 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid mixture plus sulpiride
Number of subjects: 108
Study 219500 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride alone
Number of subjects: 108
Study 219500 — intervention group
Group type: COMPARATOR
Intervention: Antacid mixture alone
Number of subjects: 108
Study 219500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 31122876 — intervention group
Group type: COMPARATOR
Intervention: Sleep group
Number of subjects: 0
Study 31122876 — intervention group
Group type: COMPARATOR
Intervention: Combination group
Number of subjects: 0
Study 31122876 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent strategy use
Number of subjects: 0
Study 31122876 — intervention group
Group type: COMPARATOR
Intervention: Sleep group assignment
Number of subjects: 0
Study 27838576 — intervention group
Group type: EXPERIMENTAL
Intervention: Snapshot‐Freeze (SSF) with beta-blockers (BB)
Number of subjects: 140
Study 27838576 — intervention group
Group type: EXPERIMENTAL
Intervention: Snapshot‐Freeze (SSF) without beta-blockers (non-BB)
Number of subjects: 140
Study 27838576 — intervention group
Group type: COMPARATOR
Intervention: Standard reconstruction (STD) with beta-blockers (BB)
Number of subjects: 140
Study 27838576 — intervention group
Group type: COMPARATOR
Intervention: Standard reconstruction (STD) without beta-blockers (non-BB)
Number of subjects: 140
Study 26070917 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg orally once daily
Number of subjects: 1717
Study 26070917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1717
Study 23606201 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus 5-fluorouracil and folinic acid (OFF)
Number of subjects: 30
Study 21555689 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 377
Study 21555689 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 377
Study 21555689 — intervention group
Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 377
Study 19412127 — intervention group
Group type: COMPARATOR
Intervention: Absence of LVH (n = 285)
Number of subjects: 1447
Study 19412127 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence of LVH (n = 418)
Number of subjects: 1447
Study 19412127 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of LVH (n = 97)
Number of subjects: 1447
Study 19412127 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression of LVH (n = 155)
Number of subjects: 1447
Study 19412127 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence of LVH
Number of subjects: 1447
Study 19412127 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence and regression of LVH at 3 years
Number of subjects: 1447
Study 19412127 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of LVH
Number of subjects: 1447
Study 17145624 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor V Leiden (FVL) mutation
Number of subjects: 5000
Study 17145624 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin (PT) G20210A mutation
Number of subjects: 5000
Study 17145624 — intervention group
Group type: COMPARATOR
Intervention: Miscarriage and preeclampsia
Number of subjects: 5000
Study 15180019 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (starting dose of 0.1 mg/kg/h)
Number of subjects: 20
Study 15180019 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (starting dose of 0.25 microg/kg/h)
Number of subjects: 20
Study 15180019 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (starting dose of 0.5 microg/kg/h)
Number of subjects: 20
Study 15180019 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 microg/kg/h)
Number of subjects: 20
Study 15180019 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.25 microg/kg/h)
Number of subjects: 20
Study 15180019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramsay score of 1
Number of subjects: 20
Study 11843991 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicare Alzheimer's Disease Demonstration (MADDE)
Number of subjects: 412
Study 11843991 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 412
Study 9766304 — intervention group
Group type: EXPERIMENTAL
Intervention: tirilazad mesylate
Number of subjects: 31
Study 9766304 — intervention group
Group type: COMPARATOR
Intervention: vehicle (control)
Number of subjects: 31